LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 3546.2% from a year ago
Total equity stood at $378.69M at the end of Q1 FY2026, up 3546.2% from a year earlier and up 25.7% from the prior quarter.
Context
- Total equity amounted to 96.2% of total assets at the end of Q1 FY2026, up 42.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +3546.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 301.31M USD
- Year-over-year change
- +418.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 301.31M | +418.7% |
| FY2024 | 2024-12-31 | (94.55M) | -174.3% |
| FY2023 | 2023-12-31 | (34.47M) | -19.6% |
| FY2022 | 2022-12-31 | (28.81M) | — |
Total Equity vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total equity of $378.69M is the 6th highest of the 10 companies compared; the peer median is $399.83M.
- Its year-over-year change of +3546.2% is the highest of 10, against a peer median of +51.3%.
- Total equity amounts to 96.2% of total assets for LBRX, versus a peer median of 90.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.39B | +51.3% | +45.3% | 77.3% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $968.03M | +641.2% | +30.1% | 90.1% |
| Jun 2026 | $835.18M | -18.7% | -0.9% | 72.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $471.51M | +65.0% | +191.8% | 94.8% |
| Mar 2026 | $399.83M | +330.0% | +180.0% | 95.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $378.69M | +3546.2% | — | 96.2% |
| Mar 2026 | $263.38M | -15.1% | +3.8% | 95.7% | |
| Mar 2026 | $243.37M | +75.0% | — | 88.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M | -69.0% | — | 45.9% |
| Jun 2026 | -$201.56B | -627630.4% | — | 212.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $399.83M | +51.3% | +37.7% | 90.1% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.